# Supplementary Information

Factors Associated with Reduction in Quality of Life After SARS-CoV-2 Infection

Christian Neumann, MSc<sup>a\*</sup>, Tim J. Hartung, MD MA<sup>b,c\*</sup>, Klara Boje, BSc<sup>d</sup>, Thomas Bahmer, MD<sup>e,f</sup>, Julian Keil, PhD<sup>d</sup>, Wolfgang Lieb, MD MSc<sup>g</sup>, Katrin Franzpoetter, MSc<sup>g</sup>, Julius Welzel, MSc<sup>a</sup>, Irina Chaplinskaya-Sobol, MSc<sup>h</sup>, Matthias Endres, MD<sup>b,i,j,k,l,m</sup>, Johanna Geritz, PhD<sup>a</sup>, Karl Georg Haeusler, MD<sup>n</sup>, Peter Heuschmann, MD<sup>o,p,q</sup>, Andreas Hinz, PhD<sup>c</sup>, Sina Hopff, MD<sup>r</sup>, Anna Horn<sup>o,q</sup>, Carolin Nuernberger, MSc<sup>o,q</sup>, Lena Schmidbauer, MSc<sup>o,q</sup>, Michael Krawczak, PhD<sup>s</sup>, Anne-Kathrin Ruß, MSc<sup>g,s</sup>, Lilian Krist, MD<sup>s</sup>, Thomas Keil<sup>t</sup>, Jennifer Kudelka, MD<sup>a</sup>, Corina Maetzler, MA<sup>a</sup>, Anja Mehnert-Theuerkauf, PhD<sup>c</sup>, Felipe A. Montellano, MD<sup>n,o,u</sup>, Caroline Morbach, MD<sup>u,v</sup>, Sein Schmidt, MD<sup>w</sup>, Jan Heyckendorf, MD<sup>e,f</sup>, Flo Steigerwald<sup>b</sup>, Stefan Stoerk, MD, PhD<sup>u,v</sup>, Christina Lemhoefer MD<sup>x</sup>, Stefan Schreiber, MD<sup>e</sup>, Carsten Finke, MD<sup>b†</sup> Walter Maetzler, MD<sup>a†</sup>

- a Neurology Department, University Medical Center Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, 24105 Kiel, Germany b Charité-Universitätsmedizin Berlin, Department of Neurology and Experimental Neurology, Bonhoefferweg 3, 10117 Berlin, Germany
- c Department of Medical Psychology and Medical Sociology, University Medical Center Leipzig, Philipp-Rosenthal-Str. 55, 04103 Leipzig Germany
- d Department of general Psychologie I and Biological Psychology, Christian-Albrechts-Universität zu Kiel, Neufeldstraße 4a, 24118 Kiel, Germany
- e Internal Medicine Department I, Leibniz Lung Clinic, University Hospital Schleswig Holstein, Campus Kiel, Arnold-Heller-Str. 3, 24105 Kiel, Germany
- f Airway Research Center North (ARCN), German Center for Lung Research (DZL), Woehrendamm 80, 22927 Grosshansdorf, Germany
- g Institute for Epidemiology, Christian-Albrechts-University Kiel, Niemanndweg 11, 24105 Kiel, Germany
- h Department of Medical Informatics, University Medical Center Goettingen, Von-Siebold-Str. 3, 37075 Goettingen, Germany i Center for Stroke Research Berlin, Charitéplatz 1, 10117 Berlin, Germany
- j Excellence Cluster NeuroCure, Charitéplatz 1, 10117 Berlin, Germany
- k German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Charitéplatz 1, 10117 Berlin, Germany
- I German Centre for Cardiovascular Research (DZHK), partner site Berlin, Charitéplatz 1, 10117 Berlin, Germany
- m German Centre for mental health (DZPG), partner site Berlin, Charitéplatz 1, 10117 Berlin, Germany
- n University of Ulm, Department of Neurology, Oberer Eselsberg 45, 89081 Ulm, Germany
- o University of Wuerzburg, Institute of Clinical Epidemiology and Biometry, Josef-Schneider-Str. 2, 97080 Wuerzburg, Germany
- p University Hospital Wuerzburg, Clinical Trial Center, Oberduerrbacher Str. 6, 97080 Wuerzburg, Germany
- q University Hospital Wuerzburg, Institute for medical Data Science, Josef-Schneider-Str. 2, 97080 Wuerzburg, Germany
- r University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Kerpener Str. 62, Germany
- s Institute of Medical Informatics and Statistics, Kiel University, University Medical Center Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, 50937 Koeln, Germany
- t Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Schumannstr. 20, 10117 Berlin, Germany
- u University Hospital Wuerzburg, Department Clinical Research and Epidemiology, Comprehensive Heart Failure Center, Am Schwarzenberg 15, 97080 Wuerzburg, Germany
- v University Hospital Wuerzburg, Department for Medicine I, Oberduerrbacher Str. 6, 97080 Wuerzburg, Germany w Berlin Institute of Health at Charité Universitätsmedizin Berlin, Clinical Study Center, Anna-Louisa-Karsch-Straße 2, 10178 Berlin. Germany
- x Institute of Physical and Rehabilitation Medicine, Jena University Hospital/Friedrich-Schiller-University Jena, Am Klinikum 1, 07747 Jena, Germany
- \* contributed equally as first authors
- <sup>†</sup> contributed equally as senior authors

## Corresponding author

M. Sc. Christian Neumann Klinik fuer Neurologie Universitätsklinikum Schleswig-Holstein, Campus Kiel Arnold-Heller-Straße 3 24105 Kiel Germany

Phone: ++49+30-450-560216

E-mail: Christian.Neumann@uksh.de

ORCID iD: 0000-0002-5891-1937

Independent variables used in the recursive feature elimination and how they were measured.

Variables	Measures				
Fatigue	FACIT-Fatigue Scale				
Personal stress	PSS total score				
Cognitive functioning	MoCA total score				
Subjective cognitive decline	Yes, No				
Subjective word finding disorder	Yes, No				
Sex	Male, Female				
Age	Years				
BMI	Weight, Height				
Employment (At follow-up: Loss of employment)	Employed, Not employed (Yes, No)				
Partner	Yes, No				
Vaccinated	Yes, No				
More than 12 years education	Yes, No				
Treatment during initial SARS-CoV-2 infection	Yes, No				
Treatment at home	Yes, No				
Stationary treatment	Yes, No				
Treatment in intensive care unit	Yes, No				
Treatment with ventilation	Yes, No				
Initial infection symptoms	Number of symptoms during initial SARS-CoV-2				
, 1	infection				
Time since infection	Days between initial SARS-CoV-2 infection and				
	assessment				
Pre-diagnosed diseases					
Any neurological/psychiatric disease	Yes, No				
COPD	Yes, No				
Sleep apnea	Yes, No				
Tumor disease	Yes, No				
Depression	Yes, No				
Anxiety	Yes, No				
Migraine	Yes, No				
Remaining symptoms	Number of symptoms remaining from initial				
Nemaning symptoms	SARS-CoV-2 infection				
Smelling disturbance	Yes, No				
Impaired sense of taste	Yes, No				
Stomach pain	Yes, No				
Confusion	Yes, No				
Diarrhea	Yes, No				
	•				
Vomiting Nausea	Yes, No Yes, No				
Vertigo Coughing	Yes, No				
Coughing	Yes, No				
Hoarseness Sore threat	Yes, No				
Sore throat	Yes, No				
Running nose	Yes, No				
Chills	Yes, No				
Muscle pain	Yes, No				
Joint pain	Yes, No				
Shortness of breath	Yes, No				
Wheezing	Yes, No				
Chest pain	Yes, No				
Rash	Yes, No				
Fever	Yes, No				
Headache	Yes, No				
Hair loss	Yes, No				


Note. Highlighted variables were also selected for the follow-up Analyses. BMI, Body-Mass-Index; EQ-5D-5L, European Quality of Life 5 Dimensions 5 Level Version; FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; MoCA, Montreal Cognitive Assessment; PSS, Perceived Stress Scale.

Sociodemographic and clinical characteristics of the COVIDOM study sample at baseline.


Characteristics [N]	Baseline = 3475		Follow-Up = 2510		
sex	Missing = 2		·		
Female [N (%)]	1944 (56)	1422 (57)			
Male [N (%)]	1529 (44)				
Age [years]	()		(:-/		
18-34 [N (%)]	1078 (31)		712 (28)		
35-49 [N (%)]	952 (27)		652 (26)		
50-64 [N (%)]	1091 (31)		851 (34)		
65-88 [N (%)]	354 (10)		295 (12)		
Unemployment	334 (10)		233 (12)		
Yes [N (%)]	628 (18)				
			-		
Hadamusialat [N (04)]	Missing = 39				
Underweight [N (%)]	44 (1)		-		
Normal weight [N (%)]	1392 (40)		-		
Overweight [N (%)]	1164 (33)		-		
Obese [N (%)]	836 (24)		-		
Time between initial					
SARS-CoV-2 infection					
and baseline	1610 (17)				
6 – 9 months [N (%)]	1618 (47)		-		
9 – 12 months [N (%)]	1334 (38)		-		
≥12 months [N (%)]	523 (15)		-		
Number of initial			Missing $= 30$		
infection symptoms					
Asymptomatic [N (%)]	306 (9)		202 (8)		
1 – 5 [N (%)]	528 (15)		396 (16)		
6 – 8 [N (%)]	701 (20)		493 (20)		
9 – 11 [N (%)]	783 (23)		560 (22)		
12 – 21 [N (%)]	1157 (33)	829 (33)			
Number of remaining					
symptoms					
Asymptomatic [N (%)]	1912 (55)		1433 (57)		
1 – 5 [N (%)]	1353 (39)	974 (39)			
6 – 8 [N (%)]	155 (4)	74 (3)			
9 – 11 [N (%)]	43 (1)	24 (1)			
12 – 21 [N (%)]	12 (< 1)	5 (< 1)			
Clinically relevant	Missing = $266$		Missing = 91		
fatigue (FACIT-Fatigue					
Scale)					
Yes	689 (20)		444 (18)		
Pre-diagnosed COVID-		Missings		Missings	
19 comorbidity					
Any neurological/	841 (24)	11	602	110	
psychiatric disorder					
Depression	387 (11)	113 290		101	
Migraine	309 (10)	92 220 1			
Anxiety	108 (3)	94 71 83			
Apnea	146 (4)	70	113	101	

COPD	53 (1)	92	38	73
Tumor	48 (1)	58	30	40
EQ-5D-5L "mobility"	Missing = 176		Missing = 62	
No problems	2544 (73)		1961 (78)	
Slight problems	459 (13)		293 (12)	
Moderate problems	220 (6)		150 (6)	
Major problems	73 (2)		44 (2)	
Extreme problems	3 (< 1)		0 (0)	
EQ-5D-5L "self-care"	Missing = 172		Missing = 62	
No problems	3168 (91)		2348 (94)	
Slight problems	91 (3)		67 (3)	
Moderate problems	29 (< 1)		23 (1)	
Major problems	10 (< 1)		9 (< 1)	
Extreme problems	5 (< 1)		1 (< 1)	
EQ-5D-5L "usual	Missing = 177		Missing = 66	
activities"				
No problems	2036 (59)		1647 (66)	
Slight problems	756 (22)		522 (21)	
Moderate problems	338 (10)	176 (7)		
Major problems	150 (4)	89 (4)		
Extreme problems	18 (< 1)		10 (< 1)	
EQ-5D-5L	Missing = 170		Missing = 63	
"pain/discomfort"				
No problems	1478 (43)		1306 (52)	
Slight problems	1073 (31)		684 (27)	
Moderate problems	553 (16)		339 (14)	
Major problems	186 (5)	108 (4)		
Extreme problems	15 (< 1)		10 (< 1)	
EQ-5D-5L	Missing = 178		Missing = 63	
"anxiety/depression"				
No problems	2041 (59)		1614 (64)	
Slight problems	802 (23)	556 (22)		
Moderate problems	294 (8)	179 (7)		
Major problems	132 (4)	80 (3)		
Extreme problems	28 (< 1)		18 (< 1)	


Note. BMI, Body-Mass-Index; COPD, chronic obstructive pulmonary disease; EQ-5D-5L, European Quality of Life 5 Dimensions 5 Level Version; FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore




**Supplementary Fig. S3** Steps and sequence of data cleaning for the COVIDOM study samples. BMI, Body-Mass-Index; EQ-5D-5L, European Quality of Life 5 Dimensions 5 Level Version; FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; MoCA, Montreal Cognitive Assessment; PSS, Perceived Stress Scale; TSI, Time since infection




**Supplementary Fig. S4** Root mean square errors (RMSE) of the models calculated by recursive feature elimination using the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index at baseline as the dependent variable. It shows the model fit in dependence of the number of selected features. The dark-blue point is the number of features with the lowest RMSE. A 35-variable model was calculated as the model with the lowest RMSE of 0.1 to explain the EQ-5D-5L index. We chose a 5-variable model as the final model because the RMSE with 5 variables is only 0.005 less than the RMSE with 35 variables, while using significantly fewer variables




**Supplementary Fig. S5** Root mean square errors (RMSE) of the models calculated by recursive feature elimination using the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index at follow-up as the dependent variable. It shows the model fit in dependence of the number of selected features. The dark-blue point is the number of features with the lowest RMSE. A 10-variable model as the model with the lowest RMSE of 0.09 to explain the EQ-5D-5L index. We chose a 6-variable model as the final model because the RMSE with 6 variables was also 0.09, while using significantly fewer variables




**Supplementary Fig. S6** Root mean square errors (RMSE) of the models calculated by recursive feature elimination using the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index at baseline as the dependent variable for participants without a pre-diagnosed anxiety or depression. It shows the model fit in dependence of the number of selected features. The dark-blue point is the number of features with the lowest RMSE. A 37-variable model as the model with the lowest RMSE of 0.1 to explain the EQ-5D-5L index. We chose a 5-variable model as the final model because the RMSE with 6 variables was still 0.1, while using significantly fewer variables




**Supplementary Fig. S7** Root mean square errors (RMSE) of the models calculated by recursive feature elimination using the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index at follow-up as the dependent variable for participants without a pre-diagnosed anxiety or depression. It shows the model fit in dependence of the number of selected features. The dark-blue point is the number of features with the lowest RMSE. An 8-variable model as the model with the lowest RMSE of 0.10 to explain the EQ-5D-5L index. We chose a 6-variable model as the final model because the RMSE with 6 variables was only 0.001 less than the RMSE with 8 variables, while using significantly fewer variables




**Supplementary Fig. S8** Root mean square errors (RMSE) of the models calculated by recursive feature elimination using the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index at baseline as the dependent variable for participants with a pre-diagnosed anxiety or depression. It shows the model fit in dependence of the number of selected features. The dark-blue point is the number of features with the lowest RMSE. A 24-variable model as the model with the lowest RMSE of 0.14 to explain the EQ-5D-5L index. We chose a 3-variable model as the final model because the RMSE with 3 variables was only 0.004 lower than the RMSE with 24 variables, while using significantly fewer variables




**Supplementary Fig. S9** Root mean square errors (RMSE) of the models calculated by recursive feature elimination using the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) index at follow-up as the dependent variable for participants with pre-diagnosed anxiety or depression. It shows the model fit in dependence of the number of selected features. The dark-blue point is the number of features with the lowest RMSE. A 13-variable model as the model with the lowest RMSE of 0.10 to explain the EQ-5D-5L index. We chose a 6-variable model as the final model because the RMSE with 6 variables was still 0.10, while using significantly fewer variables




**Supplementary Fig. S10** Mean decrease in accuracy of the selected variables at baseline after a random forest regression on the training set with the European Quality of Life 5 Dimensions 5 Level Version index as the dependent variable. FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; PSS, Perceived Stress Scale




**Supplementary Fig. S11** Mean decrease in accuracy of the selected variables at follow-up after a random forest regression on the training set with the European Quality of Life 5 Dimensions 5 Level Version index as the dependent variable. FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; PSS, Perceived Stress Scale




**Supplementary Fig. S12** Mean decrease in accuracy of the selected variables at baseline after a random forest regression on the training set with the European Quality of Life 5 Dimensions 5 Level Version index as the dependent variable for participants without a pre-diagnosed anxiety or depression. FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; PSS, Perceived Stress Scale



**Supplementary Fig. S13** Mean decrease in accuracy of the selected variables at follow-up after a random forest regression on the training set with the European Quality of Life 5 Dimensions 5 Level Version index as the dependent variable for participants without a pre-diagnosed anxiety or depression. FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; PSS, Perceived Stress Scale



Supplementary Fig. S14 Mean decrease in accuracy of the selected variables at baseline after a random forest regression on the training set with the European Quality of Life 5 Dimensions 5 Level Version index as the dependent variable for participants with a pre-diagnosed anxiety or depression. FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; PSS, Perceived Stress Scale



**Supplementary Fig. S15** Mean decrease in accuracy of the selected variables at follow-up after a random forest regression on the training set with the European Quality of Life 5 Dimensions 5 Level Version index as the dependent variable for participants with pre-diagnosed anxiety or depression. FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; PSS, Perceived Stress Scale

Order of selected variables after recursive feature elimination for each final random forest regression model at baseline and follow-up.


EQ-5D-5L	During Baseline				During Follow-Up			
	Releva	ant independent	R <sup>2</sup> [%]	RMSE	Relevant independent		R <sup>2</sup> [%]	RMSE
		variables				variables		
Index	1.	FACIT-Fatigue	39.22	0.11	1.	FACIT-Fatigue	54.07	0.10
		Scale				Scale		
	2.	Muscle pain			2.	Remaining		
	3.	Remaining				symptoms		
		symptoms			3.	PSS		
	4.	PSS			4.	Muscle pain		
	5.	Age			5.	Joint pain		
					6.	Age		
Index –	1.	FACIT-Fatigue	34.54	0.09	1.	FACIT-Fatigue	43.26	0.09
participants		Scale				Scale		
without a	2.	Remaining			2.	Remaining		
pre-		symptoms				symptoms		
diagnosed		baseline				follow-up		
neurological/	3.	PSS			3.	PSS		
psychiatric	4.	Age			4.	Age		
disorder	5.	Muscle pain			5.	Muscle pain		
					6.	Joint pain		
Index –	1.	FACIT-Fatigue	30.22	0.15	1.	FACIT-Fatigue	53.25	0.11
participants		Scale				Scale		
with at least	2.	Remaining			2.	PSS		
one pre-		symptoms			3.	Age		
diagnosed		baseline			4.	Muscle pain		
neurological/	3.	PSS			5.	Remaining		
psychiatric						symptoms		
disorder					6.	Joint pain		

Note. EQ-5D-5L, European Quality of Life 5 Dimensions 5 Level Version; FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness – Fatigue Subscore; PSS, Perceived Stress Scale

Coefficient of determination ( $R^2$ ) and root mean square error (RMSE) for each dimension of the EQ-5D-5L at baseline and follow-up

EQ-5D-5L	During I	Baseline	During Follow-Up		
	$R^2$ [%]	RMSE	$R^2$ [%]	RMSE	
Mobility	28.58	0.61	23.43	0.59	
Self-Care	3.68	0.31	13.60	0.29	
Usual activities	47.12	0.62	51.04	0.55	
Pain/discomfort	37.76	0.72	39.56	0.70	
Anxiety/depression	29.37	0.71	43.00	0.62	

Note. Calculated using random forest regression models with FACIT-Fatigue Scale, age, PSS, number of symptoms remaining from initial SARS-CoV-2 infection, and muscle pain as independent variables. EQ-5D-5L, European Quality of Life 5 Dimensions 5 Level Version; FACIT-Fatigue Scale, Functional Assessment of Chronic Fatigue Illness — Fatigue Subscore; PSS, Perceived Stress Scale



**Supplementary Fig. S18** Root mean square errors (RMSE) of the models calculated by recursive feature elimination predicting the European Quality of Life 5 Dimensions 5 Level Version EQ-5D-5L index at follow-up using baseline variables. It shows the model fit in dependence of the number of selected features. The dark-blue point is the number of features with the lowest RMSE. A 5-variable model was calculated as the model with the lowest RMSE of 0.12 to explain the EQ-5D-5L index.